Biotech company Amyris has secured a $30 million commitment this year from oil giant Total to expand fuel production from sugar cane.
Amyris yesterday announced that Total will budget $82 million over the next three years for further research and development around biofuels and the two companies intend to create a joint biofuel venture. It is an expansion of an existing partnership between the two companies to make fuels in Brazil.
The investment, announced with Amyris quarterly earnings, puts Amyris more firmly on the biofuel track. Earlier this year, the company’s operations in Brazil ran into snags making biofuels and scaled back production plans, (see “Why Amyris is Focusing on Moisturizers, Not Fuel, for Now”.)
The deal with Total “reaffirms” the companies’ commitment to making renewable farnesene from sugar cane, which can be converted to diesel and jet fuel. “In addition to Amyris’ continued development of jet and diesel businesses in Brazil independently, this enhanced collaboration provides a global platform for the future growth in fuels under a future joint venture with Total,” Amyris CEO John Melo said in a statement.
Amyris has designed genetically engineered microbes to consume sugar and make desired products, such as fuel and industrial chemicals. Scaling up the process and competing with petroleum-derived products, however, has proved challenging for Amyris and a host of other biofuel and biochemical companies, leading to delays and failed companies.
A number of small biotech companies have chosen instead to make higher-margin chemicals from sugar cane or corn, (see “To Survive, Some Biofuels Companies Give Up on Biofuels.”) Over the longer term, biofuels offer the potential of a much larger market.
Meta has built a massive new language AI—and it’s giving it away for free
Facebook’s parent company is inviting researchers to pore over and pick apart the flaws in its version of GPT-3
The gene-edited pig heart given to a dying patient was infected with a pig virus
The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.
Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging
The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.
Yann LeCun has a bold new vision for the future of AI
One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.